Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aerpio Pharmaceuticals stock

Learn how to easily invest in Aerpio Pharmaceuticals stock.

Aerpio Pharmaceuticals Inc is a biotechnology business based in the US. Aerpio Pharmaceuticals shares (ARPO) are listed on the NASDAQ and all prices are listed in US Dollars. Aerpio Pharmaceuticals employs 12 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Aerpio Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARPO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Aerpio Pharmaceuticals stock price (NASDAQ: ARPO)

Use our graph to track the performance of ARPO stocks over time.

Aerpio Pharmaceuticals shares at a glance

Information last updated 2021-10-31.
Latest market close$1.70
52-week range$0.00 - $0.00
50-day moving average $31.63
200-day moving average $25.85
Wall St. target price$22.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.41

Buy Aerpio Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aerpio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aerpio Pharmaceuticals price performance over time

Historical closes compared with the close of $1.7 from 2021-05-28

1 week (2022-09-23) N/A
1 month (2022-08-31) N/A
3 months (2022-06-30) N/A
6 months (2022-03-31) N/A
1 year (2021-09-30) N/A
2 years (2020-10-02) 16.44%
3 years (2019-10-04) 161.62%
5 years (2017-10-04) 6.25

Aerpio Pharmaceuticals financials

Gross profit TTM $15 million
Return on assets TTM -31.02%
Return on equity TTM -47.61%
Profit margin 0%
Book value $0.74
Market capitalisation $104.9 million

TTM: trailing 12 months

Aerpio Pharmaceuticals share dividends

We're not expecting Aerpio Pharmaceuticals to pay a dividend over the next 12 months.

Aerpio Pharmaceuticals share price volatility

Over the last 12 months, Aerpio Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

ARPO.US volatility(beta: 1.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aerpio Pharmaceuticals's is 1.6466. This would suggest that Aerpio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aerpio Pharmaceuticals overview

Aerpio Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease.

Frequently asked questions

What percentage of Aerpio Pharmaceuticals is owned by insiders or institutions?
Currently 4.274% of Aerpio Pharmaceuticals shares are held by insiders and 71.053% by institutions.
How many people work for Aerpio Pharmaceuticals?
Latest data suggests 12 work at Aerpio Pharmaceuticals.
When does the fiscal year end for Aerpio Pharmaceuticals?
Aerpio Pharmaceuticals's fiscal year ends in December.
Where is Aerpio Pharmaceuticals based?
Aerpio Pharmaceuticals's address is: 9987 Carver Road, Cincinnati, OH, United States, 45242
What is Aerpio Pharmaceuticals's ISIN number?
Aerpio Pharmaceuticals's international securities identification number is: US00810B1052
What is Aerpio Pharmaceuticals's CUSIP number?
Aerpio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 00810B105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site